Of interest...small medical progress
November 23, 2011 Dexpramipexole Phase 2 Results Show Efficacy in ALS
Clinical trial data for the experimental drug show slowing of symptom progression and increase in survival time in people with ALS
In a two-part phase 2 clinical trial, dexpramipexole was safe and well-tolerated in people with ALS. Additionally, the experimental treatment showed dose-related slowing of functional decline and extension of survival time. Knopp Biosciences in Pittsburgh, Pa., and Biogen Idec in Weston, Mass., have partnered to develop dexpramipexole as an experimental treatment for ALS. A large phase 3 trial of dexpramipexole has launched in 28 U.S. locations and 10 other countries.